Sort
4,870 grants matching “glp 1”
Rapid Magnetomotive Thrombolysis for Stroke
$746,315Francis Milton Creighton · Pulse Therapeutics, Inc. · R44 · FY2015 · NS
Treating Alzheimer's disease by reducing brain insulin resistance with incretin receptor agonists
$746,208Konrad Talbot · Loma Linda University · R01 · FY2019 · AG
GLP-1R agonist immune targets in lean and obesity-associated asthma
$746,134Katherine N Cahill · Vanderbilt University Medical Center · R01 · FY2024 · AI
GLP-1R agonist immune targets in lean and obesity-associated asthma
$745,797Katherine N Cahill · Vanderbilt University Medical Center · R01 · FY2025 · AI
Advancing a broad-spectrum anti-influenza A virus RNA packaging inhibitor to an IND
$745,482Jeffrey S Glenn · Stanford University · R01 · FY2020 · AI
3D Printed Silicon Nitride Porous PEEK Composite Spinal Cages for Anti-Infection
$745,427Ryan Bock · Sintx Technologies, Inc. · R44 · FY2025 · AR
Development of a Once-Weekly AND Glucose-Responsive Insulin Formulation
$745,249Matthew Webber · University Of Notre Dame · R01 · FY2025 · DK
Clinical Trials and Ancillary Assays
$745,000Harriet L Robinson · Geovax, Inc. · U19 · FY2010 · AI
Development and Pre-Clinical Trial Qualification of a Pediatric Pump-Lung System for Children
$744,248Bartley Perry Griffith · University Of Maryland Baltimore · R01 · FY2021 · HL
Biobehavioral Studies of Obesity, Weight loss and Recidivism
$743,056Ranganath Muniyappa · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2022 · DK
The effect of endogenous GLP-1 secretion on islet function in vivo
$742,934Adrian Vella · Mayo Clinic Rochester · R01 · FY2025 · DK
Advancing a Lead Candidate Hantavirus Pulmonary Syndrome DNA Vaccine
$742,164Jay Williams Hooper · Geneva Foundation · R01 · FY2013 · AI
PRECLINICAL DEVELOPMENT OF NOVEL SMOKING CESSATION PHARMACOTHERAPIES
$742,129Nurulain T Zaveri · Astraea Therapeutics, Llc · R44 · FY2015 · DA
Pre-clinical Safety and Toxicology Studies of a PO-administered b-lactam-tarocin combination agent to treat methicillin susceptible and resistant staphylococci
$741,804Terry Roemer · Hackensack University Medical Center · U19 · FY2025 · AI
Molecular Antecedents of Miscarriage
$740,868Raina N Fichorova · Brigham And Women'S Hospital · R01 · FY2023 · HD
Development of an inhibitor of VEGF expression
$740,577Joseph M Colacino · Ptc Therapeutics, Inc. · R44 · FY2006 · CA
PAR2 Pepducins as a Novel Treatment of Idiopathic Pulmonary Fibrosis
$740,572Athan Kuliopulos · Oasis Pharmaceuticals · R42 · FY2020 · HL
Molecular Antecedents of Miscarriage
$740,209Raina N Fichorova · Brigham And Women'S Hospital · R01 · FY2025 · HD
Stable Glucagon for Treatment of Hyperinsulinism
$740,140Pawel Fludzinski · Amidebio, Llc · R44 · FY2019 · DK
Affordable Oral Delivery of Human Therapeutic Proteins Bioencapsulated in Plant Cells
$739,713Henry Daniell · University Of Pennsylvania · R01 · FY2023 · HL
Affordable Oral Delivery of Human Therapeutic Proteins Bioencapsulated in Plant Cells
$739,713Henry Daniell · University Of Pennsylvania · R01 · FY2022 · HL
The Effects of Neprilysin Inhibition on Cardiometabolic Health in Black Individuals
$739,365Pankaj Arora · University Of Alabama At Birmingham · R01 · FY2025 · HL
CV Benefits and Safety of Glucose-Lowering Therapies in Adults with Diabetes
$739,203Patrick J O'Connor · Healthpartners Institute · R01 · FY2017 · HL
A GIP Companion Drug for Enhancing Metabolic Benefits of Long-Acting GLP-1
$738,741Krishna Kumar · Velum, Inc. · R42 · FY2022 · AG
Ambient light activatable opsin based therapy for age-related macular degeneration
$737,805Samarendra Kumar Mohanty · Nanoscope Technologies, Llc · R44 · FY2022 · EY